期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 162, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2023.114595
关键词
HSV-2; Q308; Acyclovir-resistant HSV-2 strain; HSV-2/HIV-1 coinfection
HSV-2 is a common pathogen that causes genital herpes worldwide. The lack of an effective vaccine prompts the development of anti-HSV-2 agents. Q308, a small-molecule compound initially developed as an anti-HIV-1 agent, shows strong inhibitory activity against HSV-2 and acyclovir-resistant HSV-2 strains. It not only reduces viral titers in tissue but also ameliorates the cytokine storm and pathohistological changes caused by HSV-2 infection in mice, making it a promising lead compound for the development of new anti-HSV-2/HIV-1 therapies, especially against acyclovir-resistant strains.
HSV-2 is a common human pathogen worldwide that causes genital herpes. Due to the lack of an effective HSV-2 vaccine in the foreseeable future, there is an urgent need to develop effective, safe and affordable anti-HSV-2 agents. Our previous studies confirmed that a small-molecule compound, Q308, effectively inhibits the reac-tivation of latent HIV and might be developed as an anti-HIV-1 agent. Patients infected with HSV-2 are generally more susceptible to HIV-1 infection than normal humans. In this study, we found that Q308 treatment had strong inhibitory activity against both HSV-2 and acyclovir-resistant HSV-2 strains in vitro and reduced the viral titers in tissue. And this treatment effectively ameliorated the cytokine storm and pathohistological changes caused by HSV-2 infection in HSV-2-infected mice. Unlike nucleoside analogs such as acyclovir, Q308 inhibited post-viral entry events by attenuating the synthesis of viral proteins. Furthermore, Q308 treatment blocked HSV-2-induced PI3K/AKT phosphorylation due to its inhibition on viral infection and replication. Overall, Q308 treatment exhibits potent anti-HSV-2 activity by inhibiting viral replication both in vitro and in vivo. Q308 is a promising lead compound for the development of new anti-HSV-2/HIV-1 therapies, particularly against acyclovir-resistant HSV-2 strains.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据